AP3340A - Novel compounds as histamine H3 receptor ligands - Google Patents

Novel compounds as histamine H3 receptor ligands

Info

Publication number
AP3340A
AP3340A AP2013007088A AP2013007088A AP3340A AP 3340 A AP3340 A AP 3340A AP 2013007088 A AP2013007088 A AP 2013007088A AP 2013007088 A AP2013007088 A AP 2013007088A AP 3340 A AP3340 A AP 3340A
Authority
AP
ARIPO
Prior art keywords
histamine
novel compounds
receptor ligands
ligands
receptor
Prior art date
Application number
AP2013007088A
Other languages
English (en)
Other versions
AP2013007088A0 (en
Inventor
Narasimhareddy Gangadasari
Sangram Keshari Saraf
Amol Dinakar Deshpande
Original Assignee
Suven Life Science Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Science Ltd filed Critical Suven Life Science Ltd
Publication of AP2013007088A0 publication Critical patent/AP2013007088A0/xx
Application granted granted Critical
Publication of AP3340A publication Critical patent/AP3340A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2013007088A 2011-02-23 2011-06-07 Novel compounds as histamine H3 receptor ligands AP3340A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN520CH2011 2011-02-23
PCT/IN2011/000380 WO2012114348A1 (fr) 2011-02-23 2011-06-07 Nouveaux composés utilisés en tant que ligands des récepteurs h3 histaminiques

Publications (2)

Publication Number Publication Date
AP2013007088A0 AP2013007088A0 (en) 2013-08-31
AP3340A true AP3340A (en) 2015-07-31

Family

ID=54290090

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013007088A AP3340A (en) 2011-02-23 2011-06-07 Novel compounds as histamine H3 receptor ligands

Country Status (27)

Country Link
US (1) US9079888B2 (fr)
EP (1) EP2694492B1 (fr)
JP (1) JP5805792B2 (fr)
KR (1) KR101554407B1 (fr)
CN (1) CN103443093B (fr)
AP (1) AP3340A (fr)
AU (1) AU2011360550B2 (fr)
BR (1) BR112013021496B1 (fr)
CA (1) CA2827567C (fr)
CY (1) CY1116721T1 (fr)
DK (1) DK2694492T3 (fr)
EA (1) EA023260B1 (fr)
ES (1) ES2548284T3 (fr)
HR (1) HRP20151003T1 (fr)
HU (1) HUE025163T2 (fr)
IL (1) IL228019A (fr)
ME (1) ME02212B (fr)
MX (1) MX339858B (fr)
NZ (1) NZ614567A (fr)
PL (1) PL2694492T3 (fr)
PT (1) PT2694492E (fr)
RS (1) RS54248B1 (fr)
SG (1) SG192858A1 (fr)
SI (1) SI2694492T1 (fr)
SM (1) SMT201500238B (fr)
WO (1) WO2012114348A1 (fr)
ZA (1) ZA201306328B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
ES2693378T3 (es) * 2014-08-16 2018-12-11 Suven Life Sciences Limited Proceso para la producción a gran escala de diclorhidrato de N-[4-(1- ciclobutil piperidin-4-iloxi) fenil]-2-(morfolin-4-il) acetamida
AU2017313427B2 (en) * 2016-08-18 2020-01-30 Suven Life Sciences Limited Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
MX377517B (es) * 2016-08-18 2025-03-10 Suven Life Sciences Ltd Combinacion triple de agonistas inversos del receptor de histamina 3, inhibidores de acetilcolinestearasa y antagonistas del receptor nmda.
LT3806859T (lt) 2018-05-31 2025-03-25 Suven Life Sciences Limited Gydymo histamino-3 receptorių atvirkštiniu agonistu būdas
EP4251148A1 (fr) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Antagonistes/agonistes inverses du récepteur h3 de l'histamine pour le traitement d'un trouble du spectre autistique
KR20250016079A (ko) 2022-03-02 2025-02-03 항저우 바이오-신세리티 파마-테크 컴퍼니 리미티드 히스타민 h3 수용체 길항제 및 이의 약학적 용도
JP2025507903A (ja) 2022-03-02 2025-03-21 杭州百誠医薬科技股▲ふん▼有限公司 フェニル尿素系誘導体及びその医薬における使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048580A1 (en) * 2004-04-01 2010-02-25 Lisa Selsam Beavers Histamine h3 receptor agents, preparation and therapeutic uses
WO2010045306A2 (fr) * 2008-10-16 2010-04-22 Schering Corporation Dérivés d'azine et leurs méthodes d'utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725541D0 (en) * 1997-12-02 1998-02-04 Pharmacia & Upjohn Spa Amino-benzothiazole derivatives
CZ2003686A3 (cs) * 2000-08-08 2003-08-13 Ortho Mcneil Pharmaceutical, Inc. Neimidazolové aryloxypiperidiny
JP2004532834A (ja) * 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンh3受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
PT1572215E (pt) * 2002-12-20 2009-12-09 Glaxo Group Ltd Derivados de benzo[d]azepina para o tratamento de perturbações neurológicas
CA2561628C (fr) * 2004-04-01 2012-05-08 Eli Lilly And Company Agents recepteurs de l'histamine h3, preparation et utilisations therapeutiques
EP1784400B1 (fr) 2004-08-23 2015-01-14 Eli Lilly And Company Agents récepteurs de l'histamine h3, préparation et utilisations thérapeutiques
WO2009030716A1 (fr) 2007-09-06 2009-03-12 Glaxo Group Limited Dérivé de pipérazine présentant une affinité pour le récepteur h3 de l'histamine
KR20100082349A (ko) * 2007-10-17 2010-07-16 사노피-아벤티스 치환된 n-페닐-비피롤리딘 우레아 및 이의 치료적 용도
WO2009100120A2 (fr) 2008-02-04 2009-08-13 Neurogen Corporation Pipérazinyl-oxoéthyl-tétrahydropyrazolopyridines substituées par du pyridinyle
US20110046130A1 (en) 2008-03-31 2011-02-24 Evotec Ag Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
CA2721303C (fr) 2008-05-08 2016-06-28 Evotec Ag Azetidines et cyclobutanes comme antagonistes des recepteurs h3 de l'histamine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048580A1 (en) * 2004-04-01 2010-02-25 Lisa Selsam Beavers Histamine h3 receptor agents, preparation and therapeutic uses
WO2010045306A2 (fr) * 2008-10-16 2010-04-22 Schering Corporation Dérivés d'azine et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
BR112013021496A2 (pt) 2019-08-06
EA023260B1 (ru) 2016-05-31
BR112013021496B1 (pt) 2021-10-13
US20140135304A1 (en) 2014-05-15
CN103443093B (zh) 2015-02-25
DK2694492T3 (en) 2015-11-09
JP2014508761A (ja) 2014-04-10
CA2827567A1 (fr) 2012-08-30
MX2013009683A (es) 2013-10-28
PL2694492T3 (pl) 2015-12-31
HRP20151003T1 (hr) 2015-10-23
US9079888B2 (en) 2015-07-14
CN103443093A (zh) 2013-12-11
CY1116721T1 (el) 2017-03-15
ES2548284T3 (es) 2015-10-15
EP2694492A1 (fr) 2014-02-12
AU2011360550B2 (en) 2015-04-09
SI2694492T1 (sl) 2015-11-30
IL228019A (en) 2015-11-30
KR101554407B1 (ko) 2015-09-18
HUE025163T2 (en) 2016-02-29
SMT201500238B (it) 2015-10-30
WO2012114348A1 (fr) 2012-08-30
NZ614567A (en) 2014-07-25
EA201391211A1 (ru) 2014-06-30
PT2694492E (pt) 2015-10-19
AU2011360550A1 (en) 2013-09-12
EP2694492B1 (fr) 2015-07-29
KR20130133270A (ko) 2013-12-06
JP5805792B2 (ja) 2015-11-10
RS54248B1 (sr) 2016-02-29
ME02212B (fr) 2016-02-20
IL228019A0 (en) 2013-09-30
SG192858A1 (en) 2013-09-30
MX339858B (es) 2016-06-15
ZA201306328B (en) 2014-04-30
AP2013007088A0 (en) 2013-08-31
HK1187613A1 (en) 2014-04-11
CA2827567C (fr) 2015-10-27

Similar Documents

Publication Publication Date Title
TWI561522B (en) Substituted imidazopyridinyl-aminopyridine compounds
GB201106799D0 (en) Novel compounds
GB201107325D0 (en) Novel compounds
GB201112607D0 (en) Novel compounds
AP3307A (en) Heteroaryl compounds as 5-HT4 receptor ligands
ZA201306328B (en) Novel compounds as histamine h3 receptor ligands
EP2717694A4 (fr) Nouveaux composés
GB201111704D0 (en) Novel compounds
IL236437A0 (en) Acrylamide compounds as ligands for the histamine h3 receptor
ZA201301143B (en) Heterocyclyl compounds as histamine h3 receptor ligands
ZA201409244B (en) Acrylamide compounds as histamine h3 receptor ligands
GB201111308D0 (en) Novel compounds
GB201121360D0 (en) Novel compounds
GB201111409D0 (en) Novel compounds
GB201106801D0 (en) Novel compounds
GB201113757D0 (en) Novel compounds
GB201113764D0 (en) Novel compounds
GB201109514D0 (en) Novel compounds
GB201113761D0 (en) Novel compounds
GB201111229D0 (en) Novel compounds
GB201103283D0 (en) Novel compounds
GB201103073D0 (en) Novel compounds
GB201104138D0 (en) Novel compounds
GB201111416D0 (en) Novel compounds
GB201111410D0 (en) Novel compounds